세계의 인공신장 시장 : 시장 인사이트, 경쟁 환경, 시장 전망(-2032년)

Artificial Kidney Market by Product (Instruments and Consumables), End-User (Hospitals, Dialysis Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of kidney failure and technological advancements such as product launches in artificial kidney

The artificial kidney market was valued at USD 2.33 billion in 2024, growing at a CAGR of 12.80% during the forecast period from 2025 to 2032 to reach USD 6.09 billion by 2032. The demand for artificial kidneys is being significantly driven by the rising prevalence of kidney failure and end-stage renal disease (ESRD), coupled with an increasing incidence of risk factors such as diabetes, hypertension, and aging. These health concerns are contributing to the growing need for more advanced renal care solutions. Additionally, the rising demand for home-based dialysis treatments and continuous technological advancements and product launches in artificial kidney development are playing a key role in propelling market growth. Together, these factors are expected to positively influence the artificial kidney market throughout the forecast period from 2024 to 2032.

Artificial Kidney Market Dynamics:

The growing prevalence of kidney diseases, including kidney failure and end-stage renal disease (ESRD), is a major factor driving the expansion of the artificial kidney market. According to the International Society of Nephrology (ISN) 2023, Global Kidney Health Atlas (GKHA), approximately 850 million people worldwide are affected by chronic kidney disease (CKD) annually, including renal failure, highlighting the widespread impact of this condition.

In the UK, Kidney Care UK reported in May 2024, that around 3.25 million people were living with later stages of chronic kidney disease, with over 20 new cases of kidney failure developing each day. Similarly, in Canada, the Kidney Foundation's 2023 report highlighted that 1 in 10 individuals, or roughly 4 million people, were living with kidney disease as of 2021. Furthermore, the Australian Bureau of Statistics reported in 2023 that 246,200 people (approximately 1% of the population) were affected by kidney disease in 2022, further underlining the growing global burden of this health issue.

Artificial kidneys play a vital role in managing kidney failure and ESRD by performing key functions of healthy kidneys. They filter waste products, remove excess fluids, and regulate electrolyte balance, helping prevent complications like imbalances, high blood pressure, and swelling. As kidney diseases continue to rise globally, the demand for artificial kidneys is expected to grow, driving market expansion and fostering innovation in renal care solutions.

The rising incidence of risk factors such as diabetes, hypertension, and aging is significantly contributing to the growing prevalence of kidney failure, thus driving the expansion of the artificial kidney market. Diabetes, a leading cause of kidney failure, accounts for approximately 38% of cases. The increasing global prevalence of diabetes is a major concern, with the International Diabetes Federation (IDF) reported in 2023 that approximately 537 million adults aged 20 to 79 were living with diabetes in 2021. This number is projected to rise to 643 million by 2030 and 783 million by 2045. High blood sugar levels can damage the blood vessels in the kidneys, leading to diabetic nephropathy, a common cause of kidney failure.

The prevalence of heart and circulatory diseases, which often coincide with kidney dysfunction, is also growing. According to the British Heart Foundation, approximately 640 million people globally were affected by heart and circulatory diseases in 2024, with the numbers expected to rise in the coming years. Chronic high blood pressure, a common cause of heart disease, can damage kidney blood vessels, further impairing kidney function over time.

Additionally, the aging population is a significant factor in the rise of kidney-related conditions. As people age, kidney function naturally declines, increasing the risk of kidney failure. According to the World Health Organization (WHO) report published in October 2024, by 2030, 1 in 6 people worldwide will be aged 60 or older, an increase from 1 billion in 2020 to an estimated 1.4 billion. Furthermore, by 2050, the global population aged 60 and above is expected to double, reaching 2.1 billion.

The increasing focus on product development and new product launches by key players is further driving growth in the artificial kidney market. For example, in November 2021, Fresenius Medical Care introduced the FX CorAL dialyzer for hemodialysis. The dialyzer's unique fiber structure ensures that the dialysis fluid evenly washes around each fiber, enhancing the clearance of waste. The lateral blood inlet port prevents the bloodline from kinking during use, promoting a more homogeneous blood flow and improving the overall safety of the treatment. In kidney diseases, the dialyzer functions as an artificial kidney, performing vital tasks typically carried out by the natural kidneys.

Despite the growth of the market, several challenges and constraints may limit its expansion, such as complications and safety concerns, immune reactions and rejection, inability to produce EPO, and stringent regulatory approvals associated with artificial kidney, are some of the key constraints that may limit the growth of the artificial kidney market.

Artificial Kidney Market Segment Analysis:

Artificial Kidney Market by Product (Instruments and Consumables), End-User (Hospitals, Dialysis Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the artificial kidney market, the instruments category is expected to hold the largest market share in 2024. This is primarily due to the rising number of patients suffering from kidney diseases and the significant advantages that artificial kidney instruments offer in the treatment of these conditions. According to the European Parliament, over 100 million people in Europe were living with chronic kidney disease (CKD) in 2022, with projections indicating a continued rise in the coming years. This trend is also observed in other regions, further fueling the demand for artificial kidney instruments and thus its market growth.

Artificial kidney instruments, particularly dialyzers used in hemodialysis, perform essential functions by filtering waste products like urea, creatinine, and excess fluids from the bloodstream, effectively mimicking the role of natural kidneys. These devices also help maintain a balanced level of electrolytes such as sodium, potassium, and calcium, while regulating fluid levels. This is crucial in preventing complications like dehydration, swelling, and electrolyte imbalances. For individuals with kidney failure or End-Stage Renal Disease (ESRD), artificial kidneys provide a life-saving solution, enabling patients to manage their condition more effectively and improve their quality of life.

Furthermore, innovations in product development by leading market players are further accelerating growth in this segment. For example, in March 2021, Baxter International received U.S. Food and Drug Administration (FDA) clearance for its next-generation Artificial Kidney 98 (AK 98) dialysis machine. Designed to be portable and user-friendly, the AK 98 features encrypted, two-way connectivity, enabling it to pull prescriptions directly from electronic medical records (EMR), thus simplifying workflow and enhancing data management for healthcare providers. This innovation reflects the ongoing efforts to improve the efficiency and accessibility of dialysis treatments, thereby supporting the expansion of the artificial kidney market.

North America is expected to dominate the overall artificial kidney market:

North America is expected to dominate the artificial kidney market in 2024, out of all regions. This is attributed to the rising incidence of chronic kidney diseases (CKD), including kidney failure and end-stage renal disease (ESRD), is a significant contributor to this growth. Innovations in artificial kidney technology, such as the development of wearable artificial kidneys and miniaturized dialysis devices, are also playing a crucial role in advancing the market. Additionally, the increasing demand for home-based dialysis options, combined with the presence of a well-established healthcare infrastructure, further supports the expansion of the artificial kidney market in the region. These factors collectively position North America as the leading market for artificial kidney.

According to data from the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 35.5 million adults, or 14% of the U.S. population, were estimated to suffer from chronic kidney disease (CKD) in 2023.

Additionally, data from the American Kidney Fund in 2024 reveals that about 808,000 people were living with kidney failure as of July 2024, with approximately 135,000 new cases diagnosed in 2021. Artificial kidneys, play a critical role in managing kidney failure by substituting the natural kidney's filtration functions. As the prevalence of kidney diseases continues to rise, the demand for artificial kidneys is expected to grow, supporting market growth in the region.

Rise in risk factor associated with the development of kidney failure is further driving the market growth. As per data from the American Heart Association in 2024, approximately 9.7 million adults are living with undiagnosed diabetes, 29.3 million have been diagnosed with diabetes, and 115.9 million are dealing with pre-diabetes in the United States in 2021.

According to a health report published by the Government of Canada in January 2024, it was found that 1 in every 4 people were suffering from hypertension in 2023 in Canada.

Furthermore, the growing adoption of home hemodialysis is significantly driving the market growth for artificial kidneys. According to data from the National Institutes of Health (NIH) in 2022, approximately 2.2% of patients were receiving home hemodialysis in 2021, and this figure increased to 2.4% in 2022. The rising preference for home dialysis is creating a greater demand for wearable and implantable artificial kidney devices, further propelling market growth in the region.

Public-private partnerships in the region are playing a pivotal role in fostering innovation in artificial kidney development, thereby driving market growth. For example, in August 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the American Society of Nephrology (ASN), launched a new prize competition through the Kidney Innovation Accelerator (KidneyX). This initiative aims to accelerate the development of a fully functional bioartificial kidney. By encouraging collaboration between government agencies, private companies, and research institutions, these partnerships are fueling advancements in artificial kidney technologies, further propelling the growth of the market.

Moreover, product launches by key players are further fostering the growth of the artificial kidney market in the region. For example, in March 2022, Nipro Medical Corporation announced the commercial launch of the SURDIAL(TM) DX Hemodialysis System in the U.S. This state-of-the-art hemodialysis system is designed to create an optimal dialysis treatment experience for both patients and clinicians. By improving the efficiency and comfort of dialysis treatments, such innovations contribute to the increasing adoption of artificial kidney devices and support the continued growth of the market in North America.

Artificial Kidney Market Key Players:

Some of the key market players operating in the artificial kidney market include Baxter, Fresenius Medical Care AG, B. Braun Melsungen AG, Asahi Kasei Corporation, Nipro Corporation, Nikkiso Co., Ltd., NxStage Medical, Inc., Medtronic, DaVita Inc., SB-KAWASUMI LABORATORIES, INC., Cantel Medical, Rockwell Medical, Inc., BD, Dialife SA, Trivitron Healthcare, TORAY MEDICAL CO., LTD., Lepu Medical Technology (Beijing) Co., Ltd., BenQ Dialysis Technology Corp., Quanta Dialysis Technologies Inc., Nextkidney B.V., and others.

Recent Developmental Activities in the Artificial Kidney Market:

• In September 2023, Quanta Dialysis Technologies(R) announced that it submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for an indication expansion of the Quanta(TM) Dialysis System. This compact and user-friendly hemodialysis device is approved for use in chronic and acute care settings. The new submission seeks to expand its use to include self-care, at-home hemodialysis, offering patients greater flexibility and independence in managing their condition.
• In August 2023, Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Versi(R)HD with GuideMe Software. This new self-guided interface is a complete redesign of the company's VersiHD chronic home hemodialysis (HHD) system.
• In April 2023, Medtronic and DaVita Inc. announced the launch of Mozarc Medical, an independent company dedicated to reshaping kidney health and advancing patient-centered technology solutions. The creation of Mozarc Medical aimed to accelerate innovation in kidney care and deliver transformative solutions that enhance the quality of life for patients with renal diseases. This strategic collaboration underscores both companies' commitment to advancing kidney health through cutting-edge technologies.

Key Takeaways from the Artificial Kidney Market Report Study

• Market size analysis for current Artificial Kidney Market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the Artificial Kidney market.
• Various opportunities available for the other competitors in the Artificial Kidney Market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current Artificial Kidney market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Artificial Kidney market growth in the coming future?

Target Audience who can be benefited from this Artificial Kidney Market Report Study

• Artificial Kidney product providers
• Research organizations and consulting companies
• Artificial Kidney related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Artificial Kidney
• Various end-users who want to know more about the Artificial Kidney Market and the latest technological developments in the Artificial Kidney Market.

Frequently Asked Questions for the Artificial Kidney Market:

1. What are Artificial Kidney?

• Artificial kidney is a medical device designed to perform the essential functions of a natural kidney when it fails or is unable to work effectively. Its primary role is to filter waste products, excess fluids, and toxins from the blood, helping to maintain the body's electrolyte balance and fluid levels. Artificial kidneys can come in various forms, including hemodialysis machines, which filter the blood outside the body, and emerging bioartificial kidneys, which combine biological elements with technology to mimic the natural kidney more closely.

2. What is the market for Artificial Kidney?

• The artificial kidney market was valued at USD 2.33 billion in 2024, growing at a CAGR of 12.80% during the forecast period from 2025 to 2032 to reach USD 6.09 billion by 2032.

3. What are the drivers for the Artificial Kidney market?

• The artificial kidney market is expected to experience substantial growth owing to factors such as the rising prevalence of kidney failure and end-stage renal disease (ESRD), coupled with an increasing incidence of risk factors such as diabetes, hypertension, and aging. Additionally, the rising demand for home-based dialysis treatments and continuous technological advancements and product launches in artificial kidney development are playing a key role in propelling market growth.

4. Who are the key players operating in the Artificial Kidney market?

• Some of the key market players operating in the artificial kidney market include Baxter, Fresenius Medical Care AG, B. Braun Melsungen AG, Asahi Kasei Corporation, Nipro Corporation, Nikkiso Co., Ltd., NxStage Medical, Inc., Medtronic, DaVita Inc., SB-KAWASUMI LABORATORIES, INC., Cantel Medical, Rockwell Medical, Inc., BD, Dialife SA, Trivitron Healthcare, TORAY MEDICAL CO., LTD., Lepu Medical Technology (Beijing) Co., Ltd., BenQ Dialysis Technology Corp., Quanta Dialysis Technologies Inc., Nextkidney B.V., and others.

5. Which region has the highest share in the Artificial Kidney market?

• North America is expected to dominate the artificial kidney market in 2024, out of all regions. This is attributed to the rising incidence of chronic kidney diseases (CKD), including kidney failure and end-stage renal disease (ESRD), is a significant contributor to this growth. Innovations in artificial kidney technology, such as the development of wearable artificial kidneys and miniaturized dialysis devices, are also playing a crucial role in advancing the market. Additionally, the increasing demand for home-based dialysis options, combined with the presence of a well-established healthcare infrastructure, further supports the expansion of the artificial kidney market in the region. These factors collectively position North America as the leading market for artificial kidney.

Table of Contents

1. Artificial Kidney Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Artificial Kidney Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Artificial Kidney Market Key Factors Analysis

• 5.1. Artificial Kidney Market Drivers
  • 5.1.1. The rising prevalence of kidney diseases such as kidney failure and end-stage renal disease (ESRD)
  • 5.1.2. An increasing incidence of risk factors such as diabetes, hypertension, and aging
  • 5.1.3. The rising demand for home-based dialysis treatments
  • 5.1.4. Continuous technological advancements and product launches in artificial kidney development
• 5.2. Artificial Kidney Market Restraints and Challenges
  • 5.2.1. Complications and safety concerns such as immune reactions and rejection, inability to produce EPO among others
  • 5.2.2. Stringent regulatory approvals associated with artificial kidney
• 5.3. Artificial Kidney Market Opportunity
  • 5.3.1. Increasing technological advancement in the domain of wearable, bioartificial, and implantable artificial kidney devices

6. Artificial Kidney Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Artificial Kidney Market Assessment

• 7.1. By Product
  • 7.1.1. Instruments
  • 7.1.2. Consumables
• 7.2. By End-User
  • 7.2.1. Hospitals
  • 7.2.2. Dialysis Centers
  • 7.2.3. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.1.2. Canada Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.1.3. Mexico Artificial Kidney Market Size in USD million (2022-2032)
  • 7.3.2. Europe
    • 7.3.2.1. France Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.2.2. Germany Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.2.3. United Kingdom Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.2.4. Italy Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.2.5. Spain Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.2.6. Rest of Europe Artificial Kidney Market Size in USD million (2022-2032)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.3.2. Japan Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.3.3. India Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.3.4. Australia Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.3.5. South Korea Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.3.6. Rest of Asia-Pacific Artificial Kidney Market Size in USD million (2022-2032)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.4.2. Africa Artificial Kidney Market Size in USD million (2022-2032)
    • 7.3.4.3. South America Artificial Kidney Market Size In USD Million (2022-2032)

8. Artificial Kidney Market Company and Product Profiles

• 8.1. Baxter
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Fresenius Medical Care AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. B. Braun Melsungen AG
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Asahi Kasei Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Nipro Corporation
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Nikkiso Co., Ltd.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. NxStage Medical, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Medtronic
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. DaVita Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. SB-KAWASUMI LABORATORIES, INC.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cantel Medical
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Rockwell Medical, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. BD
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Dialife SA
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Trivitron Healthcare
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. TORAY MEDICAL CO., LTD.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Lepu Medical Technology (Beijing) Co., Ltd.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. BenQ Dialysis Technology Corp.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Quanta Dialysis Technologies Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Nextkidney B.V.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us